About the Authors

Bettina Schlick

Affiliations Division of Experimental Urology, Dept. of Urology, Medical University of Innsbruck, Innsbruck, Austria, ONCOTYROL, Center for Personalized Cancer Medicine, Innsbruck, Austria

Petra Massoner

Affiliations Division of Experimental Urology, Dept. of Urology, Medical University of Innsbruck, Innsbruck, Austria, ONCOTYROL, Center for Personalized Cancer Medicine, Innsbruck, Austria

Angelika Lueking

Affiliation Protagen AG, Dortmund, Germany

Pornpimol Charoentong

Affiliation Division of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria

Mirjam Blattner

Affiliation Department of Pathology and Laboratory Medicine, Institute of Precision Medicine, Weill Medical College of Cornell University, New York, NY, United States of America

Georg Schaefer

Affiliations ONCOTYROL, Center for Personalized Cancer Medicine, Innsbruck, Austria, Department of Pathology, Medical University of Innsbruck, Innsbruck, Austria

Klaus Marquart

Affiliation Protagen AG, Dortmund, Germany

Carmen Theek

Affiliation Protagen AG, Dortmund, Germany

Peter Amersdorfer

Affiliation Protagen AG, Dortmund, Germany

Dirk Zielinski

Affiliation TARGOS Molecular Pathology GmbH, Kassel, Germany

Matthias Kirchner

Affiliation TARGOS Molecular Pathology GmbH, Kassel, Germany

Zlatko Trajanoski

Affiliation Division of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria

Mark A. Rubin

Affiliation Department of Pathology and Laboratory Medicine, Institute of Precision Medicine, Weill Medical College of Cornell University, New York, NY, United States of America

Stefan Müllner

Affiliation Protagen AG, Dortmund, Germany

Peter Schulz-Knappe

Affiliation Protagen AG, Dortmund, Germany

Helmut Klocker

helmut.klocker@i-med.ac.at

Affiliation Division of Experimental Urology, Dept. of Urology, Medical University of Innsbruck, Innsbruck, Austria

Competing Interests

The study was supported by COMET K1 Center Oncotyrol—Center for Personalized Medicine, financed by the Austrian Research Promotion Agency (FFG) and the Future Foundation of the Country of Tyrol, and Protagen AG. Petra Massoner, Georg Schaefer and Bettina Schlilck were employed by ONCOTYROL. Angelika Lueking, Klaus Marquart, Carmen Theek, Peter Amersdorfer, Stefan Müllner and Peter Schulz-Knappe were employed by Protagen AG. Stefan Müllner is the cofounder and CEO of Protagen AG. Dirk Zielinski and Matthias Kirchner were employed by TARGOS Molecular Pathology GmbH. Petra Massoner is currently affiliated as a DAAD fellow with Roche Diagnostics GmbH, however, her data included in the study were generated before that affiliation, study presented herein is independent of the fellowship or any other work related to Roche Diagnostics GmbH. Protagen AG holds a patent on “Marker Sequences for Diagnosing Prostate Cancer, and the Use Thereof”. There are no products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials as detailed online in the guide for authors.

Author Contributions

Conceived and designed the experiments: BS PM PA PSK SM HK. Performed the experiments: BS PM AL MB GS DZ MK. Analyzed the data: BS PC CT KM ZT DZ MAR. Contributed reagents/materials/analysis tools: GS SM DZ PSK. Wrote the paper: BS PA HK. Supervision of the project: HK SM PA.